Featured Research

from universities, journals, and other organizations

Alternative To Chemotherapy Effective For Newly Diagnosed Multiple Myeloma, Mayo Clinic Study Finds

Date:
November 1, 2002
Source:
Mayo Clinic
Summary:
A Mayo Clinic study indicates patients who are newly diagnosed with multiple myeloma, a cancer of the bone marrow, may have a new and better-tolerated option to intravenous chemotherapy treatment.

ROCHESTER, Minn. -- A Mayo Clinic study indicates patients who are newly diagnosed with multiple myeloma, a cancer of the bone marrow, may have a new and better-tolerated option to intravenous chemotherapy treatment.

Related Articles


The study will be published in the Nov. 1, 2002, issue of the Journal of Clinical Oncology. It is the first study to show that the oral combination of the drugs thalidomide plus dexamethasone provides treatment benefits equal to and in some cases better than the usual chemotherapy regimens administered to patients who are newly diagnosed with multiple myeloma. Previous studies at the University of Arkansas, Mayo Clinic and other cancer centers in the United States confirmed the use of thalidomide as an effective treatment for patients with relapsed multiple myeloma who had failed all other standard treatments.

The new study was a phase II clinical trial of 50 patients with newly diagnosed, active multiple myeloma. These patients ranged in age from 33 to 78. Of the 50 patients, 32 patients (64 percent) achieved a 50 percent or greater reduction in the amount of their tumor with the thalidomide plus dexamethasone treatment.

"The goal of both the standard chemotherapy approach and our research on the use of thalidomide plus dexamethasone is to reduce the amount of the cancer so patients can undergo stem cell retrieval and transplantation," says Vincent Rajkumar, M.D., a Mayo Clinic hematologist/oncologist and lead researcher on the study.

"Our study with thalidomide plus dexamethasone represents a significant advancement because physicians now have an alternative to the more toxic and cumbersome chemotherapy regimens used to treat patients with newly diagnosed myeloma," says Dr. Rajkumar. "For patients who are newly diagnosed with multiple myeloma, the study means they may not need to receive the series of intravenous chemotherapy treatments, and they won't experience the side effects often seen with such chemotherapy, including nausea, vomiting and hair loss."

"The toxicity of thalidomide plus dexamethasone appears lower and the response rate is as good or better than that obtained using complex combinations of chemotherapy regimens," he says. "The most serious side effect seen in six patients in the study involved blood clots in the legs. Other side effects included constipation, skin rash, numbness in the hands and feet, and sleepiness."

He added that patients who are not candidates for stem cell transplantation may have the option to continue the thalidomide plus dexamethasone treatment at reduced doses.

Despite these encouraging and promising results, Dr. Rajkumar cautions that further studies are needed before the thalidomide plus dexamethasone treatment can be recommended for routine clinical use in patients. For that purpose, Dr. Rajkumar is now leading an Eastern Cooperative Oncology Group phase III clinical trial to investigate the effectiveness of thalidomide plus dexamethasone versus only dexamethasone for treatment of patients newly diagnosed with multiple myeloma. The results of this randomized trial will help establish the role of thalidomide plus dexamethasone in the initial treatment of multiple myeloma.

Although multiple myeloma accounts for only one percent of all cancers, it is among the most difficult cancers to treat and cure. This year, about 14,000 new cases of the cancer will be diagnosed in the United States, and more than 11,000 patients will die from it. The average survival time for a patient diagnosed with multiple myeloma is about three to four years.

But there is significant hope based on promising results seen with thalidomide and other novel agents that the survival time can be significantly improved.

Thalidomide entered the medical treatment field in the mid-1950s as a sleeping pill. The drug was subsequently found to effectively control morning sickness during pregnancy. Later, the drug was found to cause severe malformations of the arms, legs and organs in an unborn child. By 1962, thalidomide was taken off the market worldwide.

In the last 10 years, researchers began studying thalidomide again as an anti-cancer agent. Although the exact mechanism of action in multiple myeloma is still unknown, researchers have found the drug effectively decreases the blood supply to cancers. It also boosts the immune system to better fight cancer.

Dexamethasone is a steroid medication that has been used for decades as the cornerstone of myeloma therapy.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Alternative To Chemotherapy Effective For Newly Diagnosed Multiple Myeloma, Mayo Clinic Study Finds." ScienceDaily. ScienceDaily, 1 November 2002. <www.sciencedaily.com/releases/2002/11/021101071306.htm>.
Mayo Clinic. (2002, November 1). Alternative To Chemotherapy Effective For Newly Diagnosed Multiple Myeloma, Mayo Clinic Study Finds. ScienceDaily. Retrieved December 21, 2014 from www.sciencedaily.com/releases/2002/11/021101071306.htm
Mayo Clinic. "Alternative To Chemotherapy Effective For Newly Diagnosed Multiple Myeloma, Mayo Clinic Study Finds." ScienceDaily. www.sciencedaily.com/releases/2002/11/021101071306.htm (accessed December 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, December 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
The Best Protein-Filled Foods to Energize You for the New Year

The Best Protein-Filled Foods to Energize You for the New Year

Buzz60 (Dec. 19, 2014) The new year is coming and nothing will energize you more for 2015 than protein-filled foods. Fitness and nutrition expert John Basedow (@JohnBasedow) gives his favorite high protein foods that will help you build muscle, lose fat and have endless energy. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins